Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a provider of injectable solutions and services that support the containment and delivery of medicines for pharmaceutical, biotechnology and generic drug companies. News related to WST often centers on its role in injectable drug administration, its proprietary product platforms and its contract manufacturing activities.
Company announcements frequently include quarterly and annual financial results, updates to revenue and earnings guidance, and details on performance in its Proprietary Products and Contract-Manufactured Products segments. Releases have highlighted trends in High-Value Product Components and High-Value Product Delivery Devices, as well as demand for self-injection devices for therapeutic areas such as obesity and diabetes.
West’s news flow also covers product and technology developments. Recent examples include the launch of the West Synchrony™ Prefillable Syringe System, described as a system-level solution for biologics and vaccines, and updates on the SmartDose® on-body delivery platform. The company has announced a definitive agreement to sell manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie, along with related information on continued supply and ongoing project commitments.
Investors following WST news will also see disclosures about capital allocation, such as dividends and share repurchases, as well as governance and leadership changes reported via press releases and Form 8-K filings. Conference participation and investor presentations are regularly announced, providing additional context on the company’s strategy and financial outlook. This news page aggregates such updates so readers can review West’s latest reported developments, financial communications and product-related announcements in one place.
West Pharmaceutical Services, a leader in injectable drug administration solutions, will participate in the Bank of America Securities 2022 Healthcare Conference from May 9-13 in Las Vegas, presenting on May 10 at 11:20 AM PDT. Additionally, the company will present at the 42nd Annual William Blair Growth Stock Conference in Chicago on June 6 and at the Jefferies Global Healthcare Conference in New York on June 9. A live audio webcast will be available on their website, with replays for 90 days. West reported $2.83 billion in net sales in fiscal year 2021.
West Pharmaceutical Services, Inc. (WST) reported first-quarter 2022 net sales of $720 million, reflecting a 7.4% increase, with organic growth of 11%. Diluted EPS rose to $2.29, up 15.1%. The company reaffirmed its full-year net sales guidance of $3.050 billion to $3.075 billion and raised adjusted-diluted EPS guidance to $9.30 to $9.45. Additionally, a dividend of $0.18 per share will be paid on August 3, 2022. The Proprietary Products Segment grew 10.6%, while Contract-Manufactured Products saw a 6.6% decline.
West Pharmaceutical Services (NYSE: WST) will release its first-quarter 2022 financial results on April 28, 2022, before market opening. The company will conduct a conference call at 9:00 a.m. Eastern Time to discuss these results and business expectations. Interested participants can dial 877-930-8295 (U.S.) or 253-336-8738 (International) using conference ID 6690124. A live broadcast will be available on West's website, along with a slide presentation. An online archive of the call will be accessible three hours post-event until May 5, 2022.
Pneuma Systems Corporation has partnered with West Pharmaceutical Services (NYSE: WST) to enhance drug therapy patient experiences. This collaboration aims to develop drug delivery solutions utilizing Pneuma's innovative closed-loop fluid flow control platform, with West providing technical and financial support. The intravenous pump market, projected to reach USD 20.5 billion in five years, underscores the significance of this partnership. The collaboration emphasizes improvements in workflow and patient safety, as West integrates PneumaDrive™ technology into various healthcare settings.
West Pharmaceutical Services, Inc. (NYSE: WST) announced that its team members received prestigious awards at the 2022 PDA Annual Meeting in Dallas. Liang Fang and Marissa Rase were honored with the 2021 Fred Simon Award for their paper on excipient-container interactions affecting prefilled syringes. Additionally, Chief Scientific Officer Fran DeGrazio received the 2021 Edward Smith Packaging Science Award for significant contributions to pharmaceutical packaging. West continues to highlight its commitment to innovation and safety in injectable drug administration.
West Pharmaceutical Services (NYSE: WST) will participate in the 2022 PDA Annual Meeting in Exton, Pennsylvania, on April 4-6, 2022. The company plans to showcase advancements in packaging science through keynote presentations, moderated sessions, and scientific posters.
Key highlights include a presentation on a Closed-Loop Wearable Injector System for Naloxone and various poster sessions focusing on vial container closure systems and prefilled syringes. With $2.83 billion in net sales for 2021, West emphasizes its leadership in ensuring quality and stability in injectable drug products.
TYME Technologies, Inc. announces key leadership changes, appointing Christine D. Baker to its Board of Directors. With over 30 years in biotech, her expertise in business development and commercialization will guide the company's cancer therapies. Douglas A. Michels becomes Chairman of the Board, bringing 39 years of healthcare experience. The changes aim to strengthen TYME's position in developing cancer metabolism-based therapies (CMBTs™) and enhance its strategic direction.
West Pharmaceutical Services (NYSE: WST) has announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 23, 2022, at 9:00 a.m. EDT. The virtual event will feature a live audio webcast available in the 'Investors' section of its website. West specializes in high-quality injectable drug administration solutions, generating $2.83 billion in net sales in fiscal year 2021, with a workforce of approximately 10,000 across 50 sites worldwide.
West Pharmaceutical Services (NYSE: WST) has announced that Eric M. Green, the current President and CEO, will also serve as Chair of the Board starting May 24, 2022. He succeeds Patrick Zenner, who is retiring after 20 years. The company highlights Green's successful leadership during the pandemic and his focus on innovative, high-quality products. Additionally, Paolo Pucci has been appointed as the Lead Independent Director of the Board. West generated $2.83 billion in net sales in FY 2021 and employs about 10,000 team members globally.
West Pharmaceutical Services, Inc. (NYSE: WST) has declared a second-quarter 2022 dividend of $0.18 per share, payable on May 4, 2022, to shareholders on record as of April 20, 2022. The company, a leader in innovative injectable solutions, reported $2.83 billion in net sales for fiscal year 2021 and employs approximately 10,000 people across 50 sites globally. West continues to support the effective delivery of life-saving medicines, enhancing shareholder value through consistent dividends.